ArticleJournal of the Korean Academy of Child and Adolescent Psychiatry2025
Body Dysmorphic Disorder and Risperidone Abuse: Exploiting Hyperprolactinemia.
Article in Journal of the Korean Academy of Child and Adolescent Psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hyperprolactinemia and Brain Health: Exploring the Gut-Brain Axis and Therapeutic Strategies.Molecular neurobiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This case report describes a 16-year-old female with body dysmorphic disorder (BDD), tics, and social withdrawal who intentionally abused risperidone to exploit its hyperprolactinemia-induced breast enlargement, perceiving it as beneficial to her body image. Initial treatment with sertraline improved social withdrawal; however, adjunctive risperidone (0.5 mg/day) reduced tics and BDD symptoms. Elevated prolactin levels (44.85 ng/mL) triggered breast enlargement, galactorrhea, and secondary amenorrhea. The patient continued risperidone despite medical advice to discontinue it. Switching to aripiprazole normalized prolactin levels (9.13 ng/mL) and resolved the side effects, with sustained symptom control at 3-month follow-up. This case highlights the risk of antipsychotic side effects reinforcing BDD pathology and adolescents' vulnerability to medication abuse when somatic changes align with dysmorphic goals. To the best of our knowledge, this is the first report of deliberate risperidone abuse for cosmetic hyperprolactinemia in BDD. Clinicians must monitor prolactin levels, prioritize prolactin-sparing agents (e.g., aripiprazole), and consider how adverse effects may perpetuate body image disturbances in adolescents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.